Noreen M. Griffin

Noreen Griffin is the founder of Immune Therapeutics, Inc., Cytocom, Inc. and a research scientist; her career has spanned multiple disciplines over the last thirty years. Ms. Griffin was a vital part of the acquisition of the patents and licenses involving Cytocom’s multiple compounds using (Metenkephalin) and the ever expanding uses of Lodonal™ (low dose naltrexone). Ms. Griffin has founded and led a number of startup companies and has been responsible for raising multiple rounds of private and venture capital funds on behalf of clients. Ms. Griffin has owned and operated a small consulting firm located in Washington, D.C. and Florida. She has also served as CEO and vice president of a number of small public companies over the last 20 years.

Ms. Griffin has published significant medical research in multiple fields including autoimmune disease, immune modulation, influenza A and a number of cancers (gastric, melanoma, rectal cancer, colon cancer, stomach cancer, hepatocellular, lung, ovarian, pancreatic, breast, urinary bladder). In addition to the research, Ms. Griffin has filed and obtained patents in the fields of autoimmune, infectious diseases, cancer, viruses and inflammatory diseases.